Advertisement

Topics

Helsinn and MEI Pharma begin dosing in Phase III combination trial for AML

19:00 EDT 2 Aug 2017 | Net Resources International

Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase III clinical trial of pracinostat and azacitidine combination to treat adults with newly diagnosed acute myeloid leukaemia (AML).

Original Article: Helsinn and MEI Pharma begin dosing in Phase III combination trial for AML

NEXT ARTICLE

More From BioPortfolio on "Helsinn and MEI Pharma begin dosing in Phase III combination trial for AML"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...